NCT06075810RecruitingPhase 1
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 26 Sept 2023
- Start date
- 9 Nov 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- MBQ Pharma
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06075810
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 48
- From 9 Nov 2023 to the primary completion date, 31 Dec 2026
- 4 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
- Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
Other illness
- Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.
- Active malignancies other than advanced breast cancer will be excluded from the study.
Other
- The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.
- Females who are pregnant or breastfeeding.
Who the study is looking for
- The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.
- Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.
- Participants with known brain metastases may be eligible if specific conditions are met.
- Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.
- Are able to swallow capsules twice daily with a meal.
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| FDI Clinical Research Coordinator of this site? Confirm its status | San Juan | Puerto Rico | Completed |
| Precision Next Gen Oncology & Research Center Coordinator of this site? Confirm its status | Beverly Hills | United States | Recruiting |
| Sarah Cannon Research Institute SCRI Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
| Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI Coordinator of this site? Confirm its status | Sarasota | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.